Compare TORM plc (TRMD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs Viatris Inc — how do they compare? TORM plc trades at $39.81 (market cap $4.12B), while Viatris Inc trades at $17.69 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.9× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold TORM plc for 23 Days and Viatris Inc for 57 Days on average.
| TRMD | VTRS | |
|---|---|---|
Market Cap | $4.12B | $20.03B |
Volume | 2,863,116 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $41.05 | $18.27 |
52-Week Low | $19.39 | $9.74 |
Typical Hold Time | 23 Days | 57 Days |
Enterprise Value | $4.83B | $32.15B |
Dividend Yield | 11.03% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $40.19, up 3.26% today, with a bullish technical outlook from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a Q4 2025 beat but Q1 and Q2 2026 misses, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026. Cash flow improved to a net positive $6M in 2026 from a negative $113.8M in 2025.
The outlook is positive given robust fundamentals and unanimous analyst buy ratings, though risks include spot rate volatility and insider selling. Revenue growth and dividend yield present opportunities, but investors should monitor freight rate trends and execution on future earnings.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
